Elad Kedar, Orasis CEO
Orasis will ship its Vuity eye drop competitor to the FDA later this year with two PhIII wins
Orasis Pharmaceuticals probably doesn’t think it’s the underdog with the two Phase III results it has in hand for an eye drop meant to help people with age-related loss of near vision.
But once the Florida biotech ships the eye drop off to the FDA for an NDA in the second half of this year, it will go up against one of the biggest pharmas, which so happens to be the first to market with an eye drop for presbyopia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
